'Dr Gorbacheva, the Head of Business Development in Russia for Menarini, has already expressed publicly her view that Ropren® is a potential blockbuster on the basis of its efficacy in the liver disease segment alone.'
AND NOW WE HAVE HER....way to go SLA.
'Dr Gorbacheva (an accomplished clinician and medical researcher before entering the pharmaceutical business) demonstrating great knowledge of Ropren®, an excellent appreciation of its ability to deal with many different conditions, and a clear understanding of its commercial potential not only in Russia but throughout the world.'
More quality coming into the company.
'At this stage, the main priority for the company is to ensure that it has sufficient capacity to satisfy demand in Russia.'
Lets not forget all those internet sales and travellers to Russia for treatment.
I feel alot more secure holding SLA now.
SLA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)